Formulation and Optimization of Progesterone Microemulsion Using Simplex Lattice Mixture Design

Porawan Aumklad; Phuvamin Suriyaamporn; Prasopchai Patrojanasophon

doi:10.4028/p-rj4fmr

Paper Titles

Development of Floating 3D-Printed Devices for Carvedilol Tablet
p.45

Assessment of Shellac as Alternative Material for Preparation of Fused Deposition Modeling (FDM) 3D Printing Filaments
p.53

Design and Investigation of Optimal Dissolving Polymeric Microneedles for Ocular Application by Using Three-Level Factorial Design
p.63

Measurement of Surface Tension/Contact Angle of Saturated Fatty Solution for Developing In Situ Forming Drug Delivery Systems
p.69

Formulation and Optimization of Progesterone Microemulsion Using Simplex Lattice Mixture Design
p.75

Role of Simulated Body Fluid in Biofilm Formation and Growth on a Polycarbonate Material
p.81

Synthesis of Fluorinated N- Benzylaniline Derivatives and Evaluations on Anti-Tyrosinase and Anti-Melanogenic Activities
p.87

Synergistic Anticancer Activity of Cinnamon Bark Oil and Imatinib Mesylate Combination on Colorectal Cancer Cell Lines
p.93

Antimicrobial and Anti-Colorectal Cancer Activities of Some Volatile Oils
p.99

HomeKey Engineering MaterialsKey Engineering Materials Vol. 914Formulation and Optimization of Progesterone...

Formulation and Optimization of Progesterone Microemulsion Using Simplex Lattice Mixture Design

Abstract:

Progesterone (P4) is a neurosteroid hormone synthesized in both males and females, it is widely used in reproductive health and hormone replacement therapy. The aim of this study was to develop microemulsions (ME) and optimization of P4 microemulsion using a simplex lattice mixture design for enhancing the transdermal delivery of P4. Pseudo-ternary phase diagrams were generated to find the optimal ratio of the microemulsion constituents. The solubilities of P4 in different oils, surfactants, and co-surfactants were determined. The ME formulations of P4 were then prepared and optimized by simplex lattice mixture design. Each ME formulation was characterized for size, PDI, zeta potential, drug content, in vitro permeation study, and drug permeation in porcine skin. The result showed that the optimal ME formulation composed of 34.97 %w/w eugenol as the oil phase, 18.35 %w/w Labrasol^® as the surfactant, 36.69 %w/w ethanol as the cosurfactant, and 10.00% w/w water containing HPβCD (1.0 M). The optimized ME showed an appropriate size of about 178 ± 42 nm with a low polydispersity index (PDI) and almost neutral charge. The drug content of the optimized ME was about 19.9 ± 0.6 %w/w. The results of in vitro permeability showed that the optimized ME formulation was significantly higher than the drug suspension. Moreover, the P4 from the optimized ME was able to be deposited in the dermis (1.07 mg) at a higher extent than in the stratum corneum (0.65 mg). In conclusion, this study explored a formulation approach to improve the transdermal permeation of P4.

You might also be interested in these eBooks

Engineering and Industrial Technology: Materials Science

View Preview

Info:

Periodical:

Key Engineering Materials (Volume 914)

Pages:

75-80

DOI:

https://doi.org/10.4028/p-rj4fmr

Citation:

Cite this paper

Online since:

March 2022

Authors:

Porawan Aumklad*, Phuvamin Suriyaamporn, Prasopchai Patrojanasophon

Keywords:

Microemulsion, Progesterone, Simplex Lattice Mixture Design, Transdermal Drug Delivery

Export:

RIS, BibTeX

Price:

Permissions:

Request Permissions

Сopyright:

Citation:

* - Corresponding Author

References

[1] M. Hill, M. Connell, A. DeCherney, Recent advances in the development of transdermal delivery systems for treatment of infertility, Research and Reports in Transdermal Drug Delivery. (2015). http://doi.org/10.2147/rrtd.S57026.

DOI: 10.2147/rrtd.s57026

Google Scholar

[2] H. Saunders, C. Khan, T. D'Hooghe, T.B. Magnúsdóttir, I. Klingmann, S. Hrafnsdóttir, Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial, Hum Reprod. 35 (2020) 355-363. http://doi.org/10.1093/humrep/dez261.

DOI: 10.1093/humrep/dez261

Google Scholar

[3] C.W. Pouton, Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system, Eur J Pharm Sci. 29 (2006) 278-287. http://doi.org/10.1016/j.ejps.2006.04.016.

DOI: 10.1016/j.ejps.2006.04.016

Google Scholar

[4] K. Rajpoot, M. Tekade, V. Pandey, S. Nagaraja, S.R. Youngren-Ortiz, R.K. Tekade, Chapter 9 - Self-microemulsifying drug-delivery system: ongoing challenges and future ahead, in: R.K. Tekade (Ed.) Drug Delivery Systems, Academic Press, 2020, pp.393-454.

DOI: 10.1016/b978-0-12-814487-9.00009-0

Google Scholar

[5] Hosmer J, Reed R, Bentley MV, Nornoo A, Lopes LB. Microemulsions containing medium-chain glycerides as transdermal delivery systems for hydrophilic and hydrophobic drugs. AAPS PharmSciTech. 2009;10(2):589-96. https://doi.org/10.1208/s12249-009-9251-0.

DOI: 10.1208/s12249-009-9251-0

Google Scholar

[6] El Maghraby GM. Occlusive and non-occlusive application of microemulsion for transdermal delivery of progesterone: mechanistic studies. Sci Pharm. 2012;80(3):765-778.

DOI: 10.3797/scipharm.1201-01

Google Scholar

[7] B. Biruss, C. Valenta, The advantage of polymer addition to a non-ionic oil in water microemulsion for the dermal delivery of progesterone, Int J Pharm. 349 (2008) 269-273. http://doi.org/10.1016/j.ijpharm.2007.08.003.

DOI: 10.1016/j.ijpharm.2007.08.003

Google Scholar

[8] W. Rangsimawong, P. Opanasopit, T. Rojanarata, T. Ngawhirunpat, Terpene-containing PEGylated liposomes as transdermal carriers of a hydrophilic compound, Biol Pharm Bull. 37 (2014) 1936-1943. http://doi.org/10.1248/bpb.b14-00535.

DOI: 10.1248/bpb.b14-00535

Google Scholar

[9] F. Muzaffar, U. K. Singh, L. Chauhan, Review on microemulsion as futuristic drug delivery, Int J Pharm Pharm Sci. 5 (2013) 39 – 53.

Google Scholar

[10] I. Nandi, M. Bateson, M. Bari, H.N. Joshi, Synergistic effect of PEG-400 and cyclodextrin to enhance solubility of progesterone, AAPS PharmSciTech. 4 (2003). http://doi.org/10.1208/pt040101.

DOI: 10.1208/pt040101

Google Scholar

[11] K.S. Paudel, M. Milewski, C.L. Swadley, N.K. Brogden, P. Ghosh, A.L. Stinchcomb, Challenges and opportunities in dermal/transdermal delivery, Ther Deliv. 1 (2010) 109-131. http://doi.org/10.4155/tde.10.16.

DOI: 10.4155/tde.10.16

Google Scholar

[12] P. Karande, S. Mitragotri, Enhancement of transdermal drug delivery via synergistic action of chemicals, Biochimica et Biophysica Acta (BBA) - Biomembranes. 1788 (2009) 2362-2373. https://doi.org/10.1016/j.bbamem.2009.08.015.

DOI: 10.1016/j.bbamem.2009.08.015

Google Scholar